Intro to The Clinical Trials Process with Dr. Mark Slater
Mark Slater, PhD, Vice President, Research HonorHealth and Chief Executive HonorHealth Research Institute
The HonorHealth Research Institute is where world-class care and groundbreaking research meet to benefit patients.Here, leading researchers, physicians and clinical teams work together to develop new therapies, as well as provide innovative care and treatments close to home. Focused on improving patients’ health and quality of life, they provide hope today and advancements for tomorrow. Having established partnerships with Harvard, Duke, Johns Hopkins, Columbia, University of Pennsylvania, Salk Institute, TGen, University of Arizona, Arizona State University as well as with many pharmaceutical and biotechnology companies, HonorHealth Research Institute is “an institute without walls.” We strive to remain nimble so we can move quickly to provide the most advanced therapeutic options for our patients.While working on new treatments today, the HonorHealth Research Institute is also ensuring that vital research continues tomorrow. Numerous clinical trials are always underway at HonorHealth Research Institute in areas such as oncology, cardiovascular, bariatrics, trauma and orthopedics/neurology.
Daniel Von Hoff Keynote
Daniel Von Hoff, MD, FACP
Ground Broken for University of Arizona Cancer Center in Phoenix
Ground Broken for University of Arizona Cancer Center in Phoenix Ground was officially broken on the new University of Arizona Cancer Center (UACC) at St. Joseph's Hospital and Medical Center/Dignity Health outpatient facility in downtown Phoenix in February, 2013. Located on the Phoenix Biomedical Campus at 625 N. Sixth St., on the northwest corner of Fillmore and Seventh streets, the center is expected to be open in 2015. Follow the project's construction progress at www.phoenixcancercenter.org
2012 AZBio Fast Lane Award Winner - Ulthera
Beauty and Growth – Ulthera, Inc
Ulthera’s mission is to work with physicians to provide therapeutic ultrasound to improve the appearance and health of patients worldwide. The company is not only defined by its proprietary technology, but also its people. Ulthera’s team consists of experts in their respective fields who are aligned by the strength of the company’s mission and its leadership.Ulthera was founded in 2004 to leverage seven years of prior scientific research in therapeutic ultrasound for aesthetic and medical applications. In 2009, the Ulthera® System received FDA approval in the United States and is the first and only energy-based device to receive FDA clearance for a non-invasive aesthetic lift indication. The first application for Ultherapy® – the procedure enabled by the System – is a non-invasive treatment of the face to achieve a brow lift. Ulthera’s robust scientific foundation and relentless pursuit of superior clinical outcomes have resulted in the rapid global uptake of the Ulthera platform. As Ulthera continues to develop and provide more applications for its platform, the company also remains committed to bringing value to physicians and their patients.In 2006, Matt Likens was hired as President and CEO of Ulthera by founder and owner Michael Slayton, Ph. D, with the expectation of obtaining FDA approval for Ulthera’s product and service (known as Ultherapy) within three months. Less than two years into his tenure at Ulthera, Matt found himself navigating this venture capital backed start-up though the worst economic downtown since the Great Depression. The Company also found itself facing an increasing skeptical and less commercially friendly US Food and Drug Administration (FDA) regime. With both of these risks significantly threatening the Company’s viability, Matt decided to change the Company’s regulatory pathway and focus by obtaining CE Mark from the European Union prior to obtaining FDA clearance. If this bet paid off, Ulthera’s regulatory runway would be significantly reduced and the Company would be able to generate sales in the European market. These revenues would also allow the Company to lessen the need to obtain additional venture capital financing thus reducing additional dilution to the Company’s current shareholders. While risky, the core of this decision was based on the multinational experience Likens attained at Baxter and his general entrepreneurial nature. The bet ultimately paid off. Today, Ulthera is a global, growth-stage medical device company pioneering aesthetic and medical applications using its therapeutic ultrasound platform technology. More than 1,000 Ulthera Systems have been sold globally while treatments performed using the System have surpassed 100,000.
Championing Patient Safety: Ventana
Brain State Technologies05/17/2013
Hockey's Kurt Sauer uses his brain to triumph over head injury.
Unconventional Brain Treatment Aiding Injured Phoenix Coyotes Defenseman Kurt Sauer
The Arizona Republic | September 2011